首页> 外文期刊>Modern Pathology >Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders
【24h】

Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders

机译:乳房淀粉样变性:主要为AL型,一半以上患有并发的乳房血液系统疾病

获取原文
           

摘要

Amyloidosis is a disorder characterized by extracellular deposition of proteins in an abnormal fibrillar configuration. Amyloidosis can be localized or systemic and may affect any organ. Breast involvement by amyloidosis has rarely been reported. In this study, we described the characteristics of 40 cases of breast amyloidosis that were reviewed at the Division of Anatomic Pathology at Mayo Clinic from 1995 to 2011. The cohort included 39 women and 1 man with a mean age of 60 years. The type of amyloidosis, determined by immunohistochemistry or mass spectrometry-based proteomics in 26 patients, was immunoglobulin-associated in all cases (AL-kappa type in 15 (58%) cases, AL-lambda in 10 (38%) and mixed heavy and light chains (AH/AL) in 1 (4%) case). Mass spectrometry-based proteomics was able to determine the type of amyloidosis in 95% of cases tested compared with 69% of cases by immunohistochemistry. In addition to amyloidosis, the breast biopsy showed a hematologic disorder in 55% of cases, most commonly MALT lymphoma. One patient had concurrent intraductal carcinoma, but none had invasive carcinoma. Of the 15 patients seen in our institution, 53% had localized amyloidosis and 47% had extramammary amyloid involvement, which was diagnosed before breast amyloidosis in most patients. M-spike was detected in the blood in 62%. After a median follow-up of 33.5 months in 12 patients, 5 died, mostly of complications of lymphoma or leukemia. In conclusion, our findings indicate that breast amyloidosis is of the AL type in the vast majority of patients (usually kappa). It is associated with systemic amyloidosis in close to half of patients and with hematologic malignancy in the breast in over half of patients. Therefore, further work up to rule out hematologic malignancy and/or systemic amyloidosis is recommended. Mass spectrometry-based proteomics is superior to immunohistochemistry for typing of breast amyloidosis.
机译:淀粉样变性病是以蛋白质的细胞外沉积为异常纤维状构型为特征的疾病。淀粉样变性可以是局部性或全身性的,并且可能影响任何器官。很少有淀粉样变性病累及乳房的报道。在这项研究中,我们描述了40例乳房淀粉样变性的特征,这些特征在1995年至2011年间由梅奥诊所解剖病理学部门进行了回顾。该队列包括39名女性和1名男性,平均年龄60岁。在所有病例中,通过免疫组织化学或基于质谱的蛋白质组学确定的淀粉样变性类型在所有病例中均与免疫球蛋白相关(AL-kappa型占15(58%),AL-lambda占10(38%),混合重症)。轻链(AH / AL)占1(4%)的情况)。基于质谱的蛋白质组学能够确定95%的患者淀粉样变性病的类型,而通过免疫组织化学方法则可确定69%的患者。除淀粉样变性外,在55%的病例中,乳房活检还显示出血液系统疾病,最常见的是MALT淋巴瘤。一名患者并发导管内癌,但无浸润性癌。在我们机构所见的15例患者中,有53%发生了局部淀粉样变性,47%发生了乳房外淀粉样变性,大多数患者均在乳腺淀粉样变性之前被诊断出。在血液中检出M钉,占62%。在对12例患者进行33.5个月的中位随访后,有5例死亡,主要是淋巴瘤或白血病并发症。总之,我们的发现表明,在绝大多数患者(通常是卡帕)中,乳房淀粉样变性是AL型的。大约一半的患者与全身性淀粉样变性有关,一半以上的患者与乳腺癌的血液系统恶性肿瘤有关。因此,建议进一步检查以排除血液系统恶性肿瘤和/或全身性淀粉样变性。基于质谱的蛋白质组学在乳腺淀粉样变性的分型方面优于免疫组织化学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号